News

Psychedelic Stock News: Psyched Wellness (CSE: PSYC) Announces Commencement of Next Pre-Clinical Study on AME-1

Toronto, Ontario – October 7, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched”), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that KGK Science, a licensed contract research organization (CRO) in Canada, is commencing the next pre-clinical trial study on Psyched’s key proprietary extract, Amanita Muscaria (AME-1).

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News

Next Article:

0 %